AI Stock Finder
Loading...
Skip to main content
Model output · Signal date Oct. 14, 2026

Daily Signals

2475 companies scored · 2026-10-14 run in progress: 4803 of ~5379 signals so far · Total · absolute moveSwitch to Alpha · 30D 90D

Signal date 2026-10-14 Cut-offs from the 2026-10-14 run
Companies scored 2475 IC ≥ 0 · market cap ≥ $100M
Median forecast +1.01% Total · 30D
Long–short spread +2.45% Strong Buy minus Strong Sell, mean
Median IC 0.29 Spearman · 30D
Rating changes ▲ 98 ▼ 46 vs the previous run
Cross-section

Distribution of the day's forecasts

30D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

287 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
151 DNAGinkgo Bioworks Holdings, Inc. Life Sciences 0.23 $792M Unlock rating and forecasts
152 CRVSCorvus Pharmaceuticals, Inc. Life Sciences 0.33 $792M Neutral +0.92% +2.14% new
153 ARDXARDELYX, INC. Life Sciences 0.28 $777M Unlock rating and forecasts
154 GERNGERON CORP Life Sciences 0.39 $771M Unlock rating and forecasts
155 GYREGYRE THERAPEUTICS, INC. Life Sciences 0.01 $748M Unlock rating and forecasts
156 ANNXAnnexon, Inc. Life Sciences 0.42 $726M Unlock rating and forecasts
157 SANASana Biotechnology, Inc. Life Sciences 0.30 $721M Unlock rating and forecasts
158 LXRXLEXICON PHARMACEUTICALS, INC. Life Sciences 0.16 $716M Unlock rating and forecasts
159 CADLCandel Therapeutics, Inc. Life Sciences 0.04 $709M Unlock rating and forecasts
160 COLLCOLLEGIUM PHARMACEUTICAL, INC Life Sciences 0.52 $701M Neutral +0.91% +1.92% ·
161 FDMT4D Molecular Therapeutics, Inc. Life Sciences 0.04 $682M Unlock rating and forecasts
162 VSTMVerastem, Inc. Life Sciences 0.51 $675M Unlock rating and forecasts
163 AURAAura Biosciences, Inc. Life Sciences 0.44 $650M Unlock rating and forecasts
164 SLDBSolid Biosciences Inc. Life Sciences 0.41 $624M Unlock rating and forecasts
165 IMMXImmix Biopharma, Inc. Life Sciences 0.22 $622M Unlock rating and forecasts
166 WVEWave Life Sciences, Inc. Life Sciences 0.49 $619M Unlock rating and forecasts
167 ZVRAZEVRA THERAPEUTICS, INC. Life Sciences 0.28 $617M Unlock rating and forecasts
168 OLMAOlema Pharmaceuticals, Inc. Life Sciences 0.53 $614M Unlock rating and forecasts
169 DSGNDesign Therapeutics, Inc. Life Sciences 0.43 $612M Unlock rating and forecasts
170 PRMEPrime Medicine, Inc. Life Sciences 0.24 $602M Unlock rating and forecasts
171 IRWDIRONWOOD PHARMACEUTICALS INC Life Sciences 0.42 $593M Unlock rating and forecasts
172 CLYMClimb Bio, Inc. Life Sciences 0.27 $592M Unlock rating and forecasts
173 AQSTAquestive Therapeutics, Inc. Life Sciences 0.14 $586M Neutral +1.10% +4.33% ·
174 CRMDCorMedix Inc. Life Sciences 0.41 $576M Neutral +0.79% +2.14% ·
175 PHATPhathom Pharmaceuticals, Inc. Life Sciences 0.24 $566M Neutral +1.01% +3.65% ·
176 IVAInventiva S.A. Life Sciences 0.24 $555M Neutral +0.79% +1.89% ·
177 STTKShattuck Labs, Inc. Life Sciences 0.35 $551M Unlock rating and forecasts
178 EOLSEvolus, Inc. Life Sciences 0.57 $512M Unlock rating and forecasts
179 ACRSAclaris Therapeutics, Inc. Life Sciences 0.34 $511M Unlock rating and forecasts
180 CTMXCytomX Therapeutics, Inc. Life Sciences 0.02 $507M Unlock rating and forecasts
181 SGMTSagimet Biosciences Inc. Life Sciences 0.37 $496M Unlock rating and forecasts
182 MNPRMonopar Therapeutics Life Sciences 0.07 $484M Unlock rating and forecasts
183 RGNXREGENXBIO Inc. Life Sciences 0.04 $479M Unlock rating and forecasts
184 ARVNARVINAS, INC. Life Sciences 0.28 $447M Unlock rating and forecasts
185 ALLOAllogene Therapeutics, Inc. Life Sciences 0.36 $446M Unlock rating and forecasts
186 TLRYTilray Brands, Inc. Life Sciences 0.01 $445M Neutral +0.90% +2.54% ·
187 ADXNAddex Therapeutics Ltd. Life Sciences 0.01 $445M Unlock rating and forecasts
188 TKNOAlpha Teknova, Inc. Life Sciences 0.46 $441M Unlock rating and forecasts
189 NGNENeurogene Inc. Life Sciences 0.13 $431M Unlock rating and forecasts
190 NIKANIKA PHARMACEUTICALS, INC Life Sciences 0.19 $431M Unlock rating and forecasts
191 AUTLAutolus Therapeutics plc Life Sciences 0.42 $431M Unlock rating and forecasts
192 ENTXEntera Bio Ltd. Life Sciences 0.26 $431M Unlock rating and forecasts
193 PRTAPROTHENA CORP PUBLIC LTD CO Life Sciences 0.31 $429M Unlock rating and forecasts
194 OVIDOvid Therapeutics Inc. Life Sciences 0.01 $428M Unlock rating and forecasts
195 TECXTectonic Therapeutic, Inc. Life Sciences 0.02 $417M Unlock rating and forecasts
196 ASMBASSEMBLY BIOSCIENCES, INC. Life Sciences 0.14 $414M Unlock rating and forecasts
197 ZURAZura Bio Ltd Life Sciences 0.25 $405M Unlock rating and forecasts
198 SPRYARS Pharmaceuticals, Inc. Life Sciences 0.27 $403M Unlock rating and forecasts
199 CAPRCAPRICOR THERAPEUTICS, INC. Life Sciences 0.49 $400M Unlock rating and forecasts
200 MYGNMYRIAD GENETICS INC Life Sciences 0.50 $390M Unlock rating and forecasts
151–200 of 287 Previous Next
Since the previous run

Rating changes

▲ 98▼ 46
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-14) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected absolute price move over the horizon, market included. This is the number a price target is built from. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.